Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies (2020) Vol. 9, Iss. 4, pp. 58-58
Open Access | Times Cited: 77

Showing 26-50 of 77 citing articles:

Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8386-8386
Open Access | Times Cited: 3
Development and application of potency assays based on genetically modified cells for biological products
Lei Yu, Yong Zhou, Junzhi Wang
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 230, pp. 115397-115397
Closed Access | Times Cited: 8
Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
Hiroyuki Suzuki, Tomokazu Ohishi, Teizo Asano, et al.
Oncology Reports (2022) Vol. 48, Iss. 3
Open Access | Times Cited: 13
A Short Update on the Use of Monoclonal Antibodies in COVID-19
Antonio Vitiello, Michela Sabbatucci, Annarita Ponzo, et al.
The AAPS Journal (2024) Vol. 26, Iss. 2
Closed Access | Times Cited: 2
Engineering Agonistic Bispecifics to Investigate the Influence of Distance on Surface-Mediated Complement Activation
Sebastiaan M. W. R. Hamers, Aimee L. Boyle, Thomas H. Sharp
The Journal of Immunology (2024) Vol. 213, Iss. 2, pp. 235-243
Open Access | Times Cited: 2
Neuroblastoma—A Review of Combination Immunotherapy
Barbara Pieniążek, Katarzyna Cencelewicz, Patrycja Bździuch, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7730-7730
Open Access | Times Cited: 2
Therapeutic antibodies in oncology: an immunopharmacological overview
Karen Toledo‐Stuardo, Carolina Ribeiro, Fabiola González‐Herrera, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 2
Microbiome Differences in Colorectal Cancer Patients and Healthy Individuals: Implications for Vaccine Antigen Discovery
Gordon C. Ibeanu, Adekunle Babajide Rowaiye, Joel Okoli, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 749-774
Open Access | Times Cited: 2
The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells
Yaiza Senent, Beatriz Tavira, Rubén Pı́o, et al.
Cancer Letters (2022) Vol. 549, pp. 215900-215900
Open Access | Times Cited: 12
Monoclonal Antibodies in Oncology: A Decade of Novel Options
Vaibhavi Kardile, Atharva Kulkarni, B.J. Thanka Nadar, et al.
Cell Biochemistry and Biophysics (2023) Vol. 81, Iss. 3, pp. 395-408
Closed Access | Times Cited: 6
T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Rickvinder Besla, Elicia Penuel, Geoff Del Rosario, et al.
Cancer Immunology Research (2023) Vol. 12, Iss. 1, pp. 60-71
Closed Access | Times Cited: 6
Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells
Monika Bednarczyk, Carolina Medina‐Montano, Frederic Julien Fittler, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2869-2869
Open Access | Times Cited: 14
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Blood Advances (2021) Vol. 5, Iss. 19, pp. 3807-3820
Open Access | Times Cited: 13
LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity
Emilie Mausser, Ellena Nador, Joseph A. Politch, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0282147-e0282147
Open Access | Times Cited: 5
Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2
Hiroyuki Suzuki, Tomokazu Ohishi, Ren Nanamiya, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 10, pp. 7734-7748
Open Access | Times Cited: 5
Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
Ayano Nakamura, Susumu Suzuki, Jo Kanasugi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10761-10761
Open Access | Times Cited: 11
Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies
Buddadasari Snehitha, Mopuri Jyothsna, A Sai, et al.
Asian Journal of Advances in Research (2024) Vol. 7, Iss. 1, pp. 159-173
Open Access | Times Cited: 1
Stellabody: A novel hexamer‐promoting mutation for improved IgG potency
Clarissa A. Whitehead, Bruce D. Wines, Anna M. Davies, et al.
Immunological Reviews (2024)
Open Access | Times Cited: 1
A Comprehensive Review of the Mechanisms and Clinical Development of Monoclonal Antibodies in Cancer Therapy
Selen Gencsoy Eker, Gizem İNETAŞ YENGİN, Cansu Tatar, et al.
Advances in experimental medicine and biology (2024)
Closed Access | Times Cited: 1
The complement system in clinical oncology: Applications, limitations and challenges
Daniel Ajona, Mark S. Cragg, Rubén Pı́o
Seminars in Immunology (2024) Vol. 77, pp. 101921-101921
Open Access | Times Cited: 1
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches
Vitalijs Ovcinnikovs, Karin Dijkman, Gijs G. Zom, et al.
Seminars in Immunology (2024) Vol. 77, pp. 101922-101922
Open Access | Times Cited: 1
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies
Khiyam Hussain, Mark S. Cragg, Stephen A. Beers
Cancers (2021) Vol. 13, Iss. 19, pp. 4904-4904
Open Access | Times Cited: 10
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
Benjamin S. Goldberg, Chengzi I. Kaku, Jérémy Dufloo, et al.
mBio (2021) Vol. 12, Iss. 5
Open Access | Times Cited: 8
Breast Cancer Updates
Selim Sözen, Seyfi Emir
IntechOpen eBooks (2022)
Open Access | Times Cited: 5

Scroll to top